Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

0.9250 +0.0050 (+0.54%)

Streaming Delayed Price Updated: 10:06 AM EDT, May 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	12,586
Open	0.9250
Bid (Size)	0.9201 (300)
Ask (Size)	0.9798 (600)
Prev. Close	0.9200
Today's Range	0.9250 - 0.9250
52wk Range	0.7282 - 3.680
Shares Outstanding	11,540,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Here are the top movers in Thursday's session. ↗

February 05, 2026

Via Chartmill

Unusual volume stocks in Thursday's session ↗

February 05, 2026

Via Chartmill

Performance

YTD	-33.5%	-33.5%
1 Month	-6.4%	-6.4%
3 Month	+7.6%	+7.6%
6 Month	-56.3%	-56.3%
1 Year	-60.1%	-60.1%

More News

Thursday's session: top gainers and losers ↗

February 05, 2026

Via Chartmill

Discover the top movers in Thursday's pre-market session. ↗

February 05, 2026

Via Chartmill

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

February 04, 2026

Via Chartmill

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

January 28, 2026

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

January 13, 2026

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

December 26, 2025

Via Chartmill

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

December 08, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

November 18, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

November 06, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

October 22, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Why Did CytoMed Therapeutics Stock Jump 19% Today? ↗

October 14, 2025

Via Stocktwits

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

October 14, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

October 02, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

August 28, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

August 18, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 23, 2025

Via Benzinga

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

July 21, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

April 28, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

February 06, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket ↗

January 07, 2025

Via Benzinga

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor ↗

January 06, 2025

Via Benzinga

Frequently Asked Questions

Is CytoMed Therapeutics Limited - Ordinary Shares publicly traded?

Yes, CytoMed Therapeutics Limited - Ordinary Shares is publicly traded.

What exchange does CytoMed Therapeutics Limited - Ordinary Shares trade on?

CytoMed Therapeutics Limited - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares?

The ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares is GDTC on the Nasdaq Stock Market

What is the current price of CytoMed Therapeutics Limited - Ordinary Shares?

The current price of CytoMed Therapeutics Limited - Ordinary Shares is 0.9250

When was CytoMed Therapeutics Limited - Ordinary Shares last traded?

The last trade of CytoMed Therapeutics Limited - Ordinary Shares was at 05/06/26 10:06 AM ET

What is the market capitalization of CytoMed Therapeutics Limited - Ordinary Shares?

The market capitalization of CytoMed Therapeutics Limited - Ordinary Shares is 10.67M

How many shares of CytoMed Therapeutics Limited - Ordinary Shares are outstanding?

CytoMed Therapeutics Limited - Ordinary Shares has 11M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.